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INTRODUCTION
Successful vaccination against the SARS-CoV-2
virus is a decisive development in the international response to the pandemic. It also
has substantial implications for how governments and international bodies deploy their
resources, as major decisions will need to be
made in a fast-
moving and uncertain environment. Current trends in vaccine development have stimulated much commentary
on how vaccines deemed to be the safest
and most effective should be allocated, both
at the global level (to ensure access for low-
income countries)1 2 and within countries
(to prioritise critical personnel and the most
vulnerable population groups).3 We recognise the importance of mass vaccination as a
public health measure, and the crucial need
to promote equity and solidarity across countries.4 5 We also recognise that prioritisation is
required within countries so that resources are
directed to best protect life, reduce inequities
and increase public confidence. However,
based on analysis of the COVID-19 response
so far, we would argue that at least three additional forms of prioritisation are required:
between vaccines; between vaccines and other
elements of the pandemic response; and
between COVID-19 and other areas of health
provision. In each case, decision makers
should concentrate as much on infrastructure and implementation as on principles of
resource allocation.

SELECTING VACCINES: THE LONG TERM
As we have already seen, there is a temptation for governments to invest most of their
available resources in the vaccines exhibiting
the greatest promise of efficacy and safety.
However, there are many alternative vaccines
currently undergoing phase III clinical trials.
If the objective is to reduce the global burden
of COVID-19 in the long term and avoid

Summary box
►► Development of vaccines is a major breakthrough in

the fight against the SARS-CoV-2 virus.
►► Much attention has been paid to how to prioritise

between patient groups for vaccination and how to
ensure equity, especially in low-income countries,
but there are other important decisions that need to
be made.
►► These decisions include: (a) choosing between the
various vaccines that will become available, (b) continuing to invest in other aspects of the COVID-19
response and (c) balancing the COVID-19 response
with the need to invest in other healthcare that has
suffered during the pandemic.
►► Although these decisions are inherently difficult,
principles of good priority setting can be helpful;
these principles include: evidence-based and transparent decision-making, participation of stakeholders and a focus on the implementation of decisions.

deepening inequities in the process, both
vaccine cost-effectiveness and equity must be
considered.
Asssessing
cost-
effectiveness
between
vaccines is hampered by their independent
development and evaluation to date. Head-
to-head comparisons may be further compromised by the need to account for variations
in effectiveness and their ability to protect
different subpopulations. Ultimately, implementation costs are likely to prove to be as,
if not more, important than narrow cost-
effectiveness profiles in determining which
options are best suited in any given context.
Cost analysis should therefore encompass
logistical and distribution issues, which
are likely to be significant drivers of affordability and influenced by, for example, the
requirement for vaccine storage at very low
temperatures.6
Vaccine costs and cost-effectiveness should
be considered in the wider context of equity
of access and outcome, and fair allocation
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PRIORITISING ACROSS THE COVID-19 RESPONSE
The experience of COVID-19 so far has been marked by
variation in system responses and notable resource shortages for both public health and treatment measures.10
The cost of investing in mass vaccination should therefore
be weighed against the continued need for these other
public health and treatment measures, as the vaccine will
not immediately eradicate the virus. Embedding vaccination programmes in a well-resourced overall pandemic
strategy and infrastructure will help with roll-out. Contact
tracing, protective equipment, treatment and environmental mitigation strategies such as indoor ventilation
will all still be required, although in (hopefully) reducing
orders of magnitude. These tools will continue to play a
critical role in the pandemic response in contexts where
vaccines are not available for whole populations at once,
or vaccine effectiveness diminishes. Recent reports of
virus mutations in mink in Denmark and other countries
and its potential spread to humans highlight the importance of ongoing vigilance and public health investment
across the COVID-19 response.11
PRIORITISING ACROSS HEALTHCARE PROGRAMMES
An accompanying feature of the pandemic has been
the suspension of many areas of routine care, including
vaccination for preventable diseases.12 13 The ramifications of this will have to be dealt with not only in the
months ahead but for many years to come. Backlogs and
capacity constraints will result in excess mortality attributable to COVID-19—already modelled for several disease
areas such as cancer14 15 and cardiovascular disease.16 17
Catching up on backlogs will place additional, competing
demands on the resources available. Investment in vaccination will need to account for this ‘suspended care
need’ and should be weighed against the immediate and
longer term requirements for the delivery of routine
health programmes.
In lower income countries (LICs), the consequences
are especially stark, with lives lost due to a lack of routine
urgent care through unemployment, restrictions on
movement and healthcare, as well as a wider reluctance
to attend healthcare facilities due to fears of contracting
COVID-19. Furthermore, previous health emergencies,
such as the most recent Ebola outbreak in West Africa,
have shown a decline in funding for other essential
programmes such as child and maternal health services.18
The impact of further diverting scarce resources away
2

from other areas of need will therefore need to be closely
monitored and evaluated in order to understand the
potential consequences of placing a higher value on one
life saved from COVID-19 over one life saved from other
conditions.
FOCUS ON IMPLEMENTATION
Our analysis of COVID-19 international pandemic
responses highlights the critical importance of planning for effective implementation of any mass vaccination programme.19 If the global community is seriously
committed to a fair and just international COVID-19
vaccination strategy, the conversation must go beyond
mitigating inequities in nations’ purchasing power and
access to safe and effective vaccines. There are additional inequities across and within countries in terms of
the resources available for mobilisation and infrastructure in place to support a mass vaccination campaign.20
Meanwhile, the burden on agencies at the forefront of
the COVID-19 response cannot be overstated. Vaccine
roll-out, however welcome, is an additional strain not
only in LICs but also increasingly in high-income countries.21 22 There is a need to support health systems to
sustain routine services—this is more critical for weaker
health systems seeking to prevent excessive avoidable
mortality.20 Lastly, as countries plan to roll out COVID-19
vaccination, it is important that effective strategies to
deal with vaccine hesitancy are developed and implemented.23 24
CONCLUSIONS
The fundamental tenets of good priority setting include:
taking an explicit approach to decision-making; meaningful stakeholder engagement; consideration of public
values, ensuring mechanisms for appeals and revisions;
and use of relevant evidence.25 26 Furthermore, for priority
setting to be impactful, resource allocation should be
aligned with set priorities.25 27 In the case of vaccination against COVID-19, such tenets will be crucial, as
mismanaged priority setting would have disastrous consequences for health, equity and trust in public health and
policymakers. However, the challenges extend beyond
choosing which patient groups to prioritise, and there is
a risk that a narrow focus on such questions will distract
from other choices that need to be made.
When selecting between vaccines for investment,
governments should balance the requirement for
urgency with the importance of ongoing evidence-
informed decision-
making, as more becomes known
about vaccine characteristics, adverse effects, duration
of immunity and extent of protection from transmission.
In evaluating vaccine options, decision makers should
go beyond narrow cost-effectiveness profiling to assess
implementation costs, especially those that are likely
to vary across vaccines. Taking a ‘real world’ approach
to priority setting requires decision makers to accept
uncertainty with respect to the unfolding context, and
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of resources within and across populations.7 8 Though
COVID-19 vaccines may initially be funded by donors, all
countries will need long-term, mass COVID-19 vaccination strategies to ensure equitable and sustainable practices. Circumstances in which access is dependent on
out-of-pocket contributions, or where available vaccines
are perceived as unsafe and/or ineffective, will fuel inequity, antivaccine propaganda, and black and grey vaccine
markets.9
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